Commercial-stage biopharmaceutical company Agios Pharmaceuticals Inc. (AGIO) is on the cusp of a milestone that could redefine its market position. With the U.S. Food and Drug Administration (FDA) setting December 7, 2025, as the Prescription Drug User Fee Act (PDUFA) goal date for PYRUKYND's supplemental New Drug Application (sNDA) in thalassemia, market watchers are bracing for a pivotal decision. The outcome has the potential to reshape Agios's commercial profile and reestablish confidence in a stock that recently touched a 52-week low.
PYRUKYND: The PDUFA Spotlight
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.